Pharma BD Deal Intelligence
AstraZeneca PLC / Amolyt Pharma
2024 · Acquisition/Merger · $1.1B · Complete
Announcement Sentiment
94
Strongly positive
Outcome Score
73
Largely worked — most objectives met.
AstraZeneca acquired Amolyt Pharma for $1.05B for eneboparatide for hypoparathyroidism.
Key facts
- Announced Mar 14, 2024
- Closed Jul 15, 2024
- Deal value $1.1B
- Deal type Acquisition/Merger
- Therapeutic area Rare Disease
- Key assets eneboparatide
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals